Valneva SE - American Depositary Shares (VALN)

♥ 397 Thanks from members

Valneva SE faces significant earnings headwinds, wider losses, and heavy impairment charges on its chikungunya vaccine, yet maintains a solid cash position and reaffirms full-year product sales guidance as the Lyme disease vaccine program advances toward upcoming regulatory decisions.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →

Other Nasdaq Tickers

NASDAQ

Microchip Technology Incorporated (MCHP)

NASDAQ

Direxion Daily AAPL Bear 1X ETF (AAPD)

NASDAQ

Ascentage Pharma Group International - American Depository Shares (AAPG)

NASDAQ

Direxion Daily AAPL Bull 2X ETF (AAPU)

NASDAQ

Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS)

NASDAQ

AbCellera Biologics Inc. - Common Shares (ABCL)

Entity & Market Metadata

Sector: Healthcare Industry: Biotechnology & Vaccines Founder: Alain Gouraud Founder: Cyril Guillaumin Leadership: Thomas Lingelbach (CEO) Leadership: Peter Bühler (CFO) Holder: Bpifrance Holder: M&G Investment Management Holder: Global, Inc. Ixiaro Dukoral Chikungunya Vaccine Lyme Vaccine Candidate #VALN stock #Valneva SE #vaccine biotech #NASDAQ VALN #Lyme disease vaccine